Trump Relaxes Marijuana Classification with New Executive Order

0
88
Trump Relaxes Marijuana Classification with New Executive Order

Key Takeaways:

  • President Donald Trump signed an executive order to reclassify marijuana as a less dangerous drug, potentially moving it from a Schedule I to a Schedule III substance.
  • The reclassification could open new avenues for medical research and reduce the tax burden on the cannabis industry.
  • The move is a significant shift in federal drug policy, aligning with the policies of many states that have already legalized medical marijuana.
  • The reclassification would not make marijuana legal for recreational use nationwide, but could change how the drug is regulated.
  • The move has received support from many Americans, with 64% of people polled by Gallup backing a less restrictive approach to marijuana.

Introduction to the Executive Order
The President of the United States, Donald Trump, has signed an executive order that could potentially reclassify marijuana as a less dangerous drug. This move could shift marijuana from its current classification as a Schedule I drug, alongside heroin and LSD, to a Schedule III substance, like ketamine and some anabolic steroids. The reclassification, which would be carried out by the Drug Enforcement Administration (DEA), could have significant implications for medical research and the cannabis industry as a whole. According to Trump, he has received numerous phone calls from people supporting the move, citing its potential to help patients in great pain.

Current State of Marijuana Laws
Currently, medical marijuana is allowed in 40 states and Washington, D.C., and many states have also legalized it for recreational use. However, U.S. laws have remained stricter, potentially leaving people subject to federal prosecution. The Justice Department under Trump’s Democratic predecessor, Joe Biden, had previously proposed reclassifying marijuana to a Schedule III substance. Despite this, Trump’s move has not been universally welcomed, with some Republicans speaking out in opposition to any changes and urging Trump to maintain current standards. For instance, more than 20 Republican senators signed a letter this year urging the president to keep marijuana a Schedule I drug, citing concerns about its potential dangers and impact on public health and safety.

The Process of Reclassification
The process of reclassifying marijuana typically requires an arduous process, including a public comment period that has drawn tens of thousands of reactions from across the U.S. The DEA was still in the review process when Trump took office in January, and he has ordered that the process be expedited as quickly as legally possible. While an exact timeline remains unclear, the move is seen as a significant step towards aligning federal policy with the policies of many states. According to polling from Gallup, Americans largely back a less restrictive approach to marijuana, with support for legalization growing from 36% in 2005 to 64% this year. However, this support has declined slightly in recent years, primarily due to declining support among Republicans.

Impact on Research and Access to CBD
Trump’s order also calls for expanded research and access to CBD, a legal and increasingly popular hemp-derived product whose benefits to treat things like pain, anxiety, and sleep issues are debated by experts. A new Medicare pilot program would allow older adults to access legal hemp-derived CBD at no cost, if recommended by a doctor. This move is seen as a significant step towards recognizing the potential medical benefits of marijuana and providing greater access to patients who could benefit from it. For example, the U.S. Department of Health and Human Services has found that 30,000 licensed health care practitioners are authorized to recommend marijuana use for over 6 million patients for at least 15 medical conditions.

Opposition to the Move
Despite the potential benefits of the move, there is still significant opposition to the reclassification of marijuana. More than 20 Republican senators signed a letter this year urging the president to keep marijuana a Schedule I drug, citing concerns about its potential dangers and impact on public health and safety. The group, led by North Carolina Sen. Ted Budd, argued that marijuana continues to be a dangerous drug and that a shift would "undermine your strong efforts to Make America Great Again." They also argued that marijuana negatively affects users’ physical and mental health, as well as road and workplace safety. Additionally, some experts, such as Jack Riley, a former deputy administrator of the DEA, have expressed concerns that the move sends a conflicting message, given Trump’s focus on the drug war as a national security priority.

Conclusion and Future Implications
In conclusion, Trump’s executive order to reclassify marijuana as a less dangerous drug is a significant shift in federal drug policy. While the move has received support from many Americans, it has also been met with opposition from some Republicans and experts. As the process of reclassification moves forward, it will be important to consider the potential implications for medical research, the cannabis industry, and public health and safety. Ultimately, the move has the potential to provide greater access to patients who could benefit from marijuana and to recognize its potential medical benefits. However, it will also be important to address concerns about the potential dangers of marijuana and to ensure that any changes to federal policy are carefully considered and implemented.

SignUpSignUp form

LEAVE A REPLY

Please enter your comment!
Please enter your name here